Summary & Overview
CPT 80352: Toxicology Panel for Seven or More Synthetic Cannabinoids
CPT code 80352 designates a laboratory toxicology panel that detects or quantifies seven or more synthetic cannabinoids in a patient specimen. This code captures complex analytical testing typically performed in clinical or hospital laboratories using advanced instrumentation and methods. Nationally, growing concerns about synthetic cannabinoid use and variable clinical presentations make accurate laboratory identification important for patient management, public health surveillance, and forensic investigations.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for synthetic cannabinoid testing, payer coverage patterns and common modifiers used for laboratory services, and operational benchmarks for site-of-service and laboratory workflows. The publication also summarizes coding considerations, typical service locations, and areas where payers commonly request documentation or prior authorization for specialized toxicology testing.
The content is intended to inform clinical laboratory managers, billing departments, and policy analysts about how CPT code 80352 is used in practice, what stakeholders often review when adjudicating claims, and where variability in coverage and utilization can occur. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 80352 reports laboratory testing in which a laboratory analyst measures the amount of, or detects the presence of, seven or more synthetic cannabinoids in a patient specimen. This service is a toxicology panel for multiple synthetic cannabinoids and is performed by clinical laboratory personnel using specialized analytical techniques.
-
Service type: Laboratory toxicology panel for synthetic cannabinoids
-
Typical site of service: Clinical laboratory or hospital laboratory; specimens are collected in outpatient clinics, emergency departments, or inpatient settings and analyzed in a diagnostic laboratory setting
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult or adolescent who presents to an emergency department, outpatient clinic, occupational health program, substance use disorder program, correctional facility, or occupational drug testing laboratory with suspected use of synthetic cannabinoids (commonly known as K2, Spice, or synthetic marijuana) after acute behavioral changes, altered mental status, agitation, hallucinations, cardiovascular symptoms (tachycardia, hypertension), or as part of a workplace or forensic drug screen. A clinician orders comprehensive toxicology testing when standard urine or serum drug screens are negative or when there is clinical suspicion for newer synthetic cannabinoid analogs.
The clinical workflow begins with specimen collection (urine, serum, or plasma) and labeling, with proper chain-of-custody if forensically required. The specimen is sent to a clinical laboratory that performs targeted mass spectrometry or immunoassay panels configured to detect multiple synthetic cannabinoid compounds. The laboratory analyst performs qualitative or quantitative testing that identifies seven or more synthetic cannabinoid analytes, documents method and limits of detection, and reports results to the ordering provider. Results inform clinical management (supportive care, psychiatric evaluation, toxicology consultation) and may be used for public health surveillance, workplace compliance, or legal proceedings. Turnaround time varies from hours (stat) to days (routine) depending on assay complexity and instrumentation availability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |